Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 24, Issue 9, 2006, Pages 625-630

  Zighelboim, Israel ^a,c   Taylor, Nicholas P ^a   Powell, Matthew A ^a   Gibb, Randall K ^a   Rader, Janet S ^a   Mutch, David G ^a   Grigsby, Perry W ^b  

^a Washington University in St Louis School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

Cervical cancer; Chemotherapy; Metastatic; Radiotherapy; Stage IVB

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOMAGNESEMIA; INTESTINE ISCHEMIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; RADIATION DOSE; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; PLATINUM COMPOUNDS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 33846173052     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11604-006-0082-6     Document Type: Article

References (25)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. (eds). SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute, http:// seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site, 2005.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database. Incidence-SEER 9 Regs Public-Use, November 2004 Sub (1973-2002). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2005, based on the November 2004 submission.
3. Shepherd J. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
4. The revised common toxicity criteria: version 2.0. CTEP website (http://ctep.info.nih.gov).
5. Kaplan EL, Meier P. Nonparametric estimation from complete observations. J Am Stat Assoc 1958;53:457-81.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
7. Spanos WJ, Pajak TJ, Emami B, Rubin P, Cooper JS, Russell AH, et al. Radiation palliation of cervical cancer. J Natl Cancer Inst Monogr 1996;21:127-30.
8. Sommers GM, Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol 1989;35:150-5.
9. Thigpen T, Vance R, Lambuth B, Balducci L, Khansur T, Blessing J, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987;60:2104-16.
10. Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO. A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma. Cancer 1993;71:2245-9.
11. Edmonson JH, Johnson PS, Wieand HS, Malkasian GD, Cullinan SA, Brown LD, et al. Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma. Am J Clin Oncol 1988;11:149-51.
12. Buxton EJ. Experience with bleomycin, ifosfamide and cisplatin in primary and recurrent cervical cancer. Semin Oncol 1992;19:9-17.
13. Piver MS, Ghamande SA, Eltabbakh GH, O'Neill-Coppola C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phase II study. Gynecol Oncol 1999;75:334-7.
14. Zannetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A, et al. Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999;10:1171-4.
15. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999;17: 2676-80.
16. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001;19:1275-8.
17. Long III HJ, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, et al. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin and cisplatin with or without the addition of molgramostim and review of the literature. Am J Clin Oncol 2002;25:547-51.
18. Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D., et al. Combination of ifosfamide, paclitaxel and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 2002;85:476-82.
19. Cerrotta A, Gardan G, Cavina R, Raspagliesi F, Stafanon B, Garassino I, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix: a pilot study with intensification dose. Eur J Gynaecol Oncol 2002;23:115-9.
20. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 2003;89: 402-7.
21. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.
22. Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent or metastatic cervical carcinoma. Gynecol Oncol 2004;92:635-8.
23. Long III HJ, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2005;23:4626-33.
24. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study. Gynecol Oncol 2005;96:8059.
25. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L. Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358:781-6.